Clinical trial · Observational
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
NCT05572645CI-TRIAL-00074343completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pertuzumab Plus Trastuzumab | Drug | Pertuzumab/Trastuzumab Regimen | ALIAS |
| Pyrotinib Plus Trastuzumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PyroH
- description
- treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
- interventionNames
- Drug: Pyrotinib Plus Trastuzumab
- label
- PertH
- description
- treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
- interventionNames
- Drug: Pertuzumab Plus Trastuzumab
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive. * Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep 2022. * Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions. Exclusion Criteria: * Incomplete medical history
References
Publications (1)
- DERIVEDYou S, Xie Y, Sang D, Luo T, Yuan P, Xu F, Wang B. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis. Front Endocrinol (Lausanne). 2023 Dec 11;14:1325540. doi: 10.3389/fendo.2023.1325540. eCollection 2023. PMID 38149099